Darlene Fontanazza
Acute Care · Edison, NJNPI 1992726905
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 273 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by GSK at 48.4% of the total. Among acute care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$787
- Amgen$449
- Philips North America LLC$386
- Mylan Specialty L.p.$215
- Boehringer Ingelheim$181
- plus $739 from 17 others
What the payments were for
- Food & beverage$5,344100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 125 | $2,587 |
| AstraZeneca | 28 | $787 |
| Amgen | 25 | $449 |
| Philips North America LLC | 24 | $386 |
| Mylan Specialty L.p. | 19 | $215 |
| Boehringer Ingelheim | 12 | $181 |
| Pulmonx Corporation | 2 | $111 |
| Grifols USA, LLC | 5 | $98 |
| Sanofi | 5 | $87 |
| Insmed, Inc. | 5 | $81 |
| Inspire Medical Systems, Inc. | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $48 |
| Electromed, Inc. | 5 | $46 |
| Verona Pharma, Inc. | 2 | $36 |
| Baxter Healthcare | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Lilly USA, LLC | 1 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Viatris Specialty LLC | 1 | $16 |
| Harmony Biosciences LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$829
- TEZSPIRE$130
- AREXVY$125
- TRELEGY ELLIPTA$104
How this compares
$5,344 in reported general payments places this provider in the 95th percentile of 656 acute care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 20 | $89,300 |
| NucalaMepolizumab | 23 | $85,968 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $85,888 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $30,505 |
| Spiriva RespimatTiotropium Bromide | 42 | $27,653 |
| EliquisApixaban | 14 | $13,573 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,365 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,864 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,340 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,796 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,861 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,778 |
| Montelukast Sodium | 145 | $1,713 |
| Azelastine Hcl | 11 | $509 |
| Atorvastatin Calcium | 20 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $2,587 | $190,085169 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $787 | $123,60171 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $181 | $32,99353 claims |
| PfizerEliquis | $15 | $13,57314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 656 acute care providers in New Jersey.
Other acute care in Edison
- Gabriella MagarelliHackensack$44K
- Per RosenkvistLivingston$29K
- Matthew OstroffPaterson$27K
- Ellen McCueNeptune$26K
- Suzanne ShuggLivingston$25K
- Maria Tedi CoronelHackensack$19K
- Hanane ChaibainouWestampton$16K
- Jennifer McCarthyNewark$16K
- Jennifer HarrarCamden$16K
- Vincent FroncekFlemington$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.